% alzhub.org library filter
% Source: https://alzhub.org/research?author=Hofmann+C
% 6 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{josephmathurin2022-36151869,
  author  = {Joseph-Mathurin, N. and Llibre-Guerra, J. J. and Li, Y. and McCullough, A. A. and Hofmann, C. and Wojtowicz, J. and Park, E. and Wang, G. and others},
  title   = {{Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease}},
  journal = {Annals of neurology},
  year    = {2022},
  doi     = {10.1002/ana.26511},
  pmid    = {36151869},
  url     = {https://doi.org/10.1002/ana.26511}
}

@article{portron2020-31883703,
  author  = {Portron, A. and Jordan, P. and Draper, K. and Muenzer, C. and Dickerson, D. and van Iersel, T. and Hofmann, C.},
  title   = {{A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers}},
  journal = {Clinical therapeutics},
  year    = {2020},
  doi     = {10.1016/j.clinthera.2019.11.015},
  pmid    = {31883703},
  url     = {https://doi.org/10.1016/j.clinthera.2019.11.015}
}

@article{aldea2022-35676943,
  author  = {Aldea, R. and Grimm, H. P. and Gieschke, R. and Hofmann, C. and Lott, D. and Bullain, S. and Delmar, P. and Klein, G. and others},
  title   = {{In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model}},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  year    = {2022},
  doi     = {10.1002/trc2.12306},
  pmid    = {35676943},
  url     = {https://doi.org/10.1002/trc2.12306}
}

@article{klein2019-31831056,
  author  = {Klein, G. and Delmar, P. and Voyle, N. and Rehal, S. and Hofmann, C. and Abi-Saab, D. and Andjelkovic, M. and Ristic, S. and others},
  title   = {{Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis}},
  journal = {Alzheimer's research \& therapy},
  year    = {2019},
  doi     = {10.1186/s13195-019-0559-z},
  pmid    = {31831056},
  url     = {https://doi.org/10.1186/s13195-019-0559-z}
}

@article{grimm2023-37823690,
  author  = {Grimm, H. P. and Schumacher, V. and Schäfer, M. and Imhof-Jung, S. and Freskgård, P. O. and Brady, K. and Hofmann, C. and Rüger, P. and others},
  title   = {{Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans}},
  journal = {mAbs},
  year    = {2023},
  doi     = {10.1080/19420862.2023.2261509},
  pmid    = {37823690},
  url     = {https://doi.org/10.1080/19420862.2023.2261509}
}

@article{retout2022-35100444,
  author  = {Retout, S. and Gieschke, R. and Serafin, D. and Weber, C. and Frey, N. and Hofmann, C.},
  title   = {{Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease}},
  journal = {Clinical pharmacology and therapeutics},
  year    = {2022},
  doi     = {10.1002/cpt.2535},
  pmid    = {35100444},
  url     = {https://doi.org/10.1002/cpt.2535}
}